Kaya Ltd Q2 FY26 Earnings Analysis

- Kaya Limited aims to improve growth from its current 7%-8% in Q1 FY ‘26 towards the industry growth rate of 13%-14% over the next five years. - Growth initiatives include better utilization of existing clinic infrastructure and investment in marketing and customer acquisition. - Expansion program underway with 2 new clinics opened in Q1, 1 in Q2, and 5 signed, targeting around 8 new clinics by Sept-Oct 2025. - Product development contributes 5% and new service development 6% to clinic collections, supporting revenue growth. - Kaya Smiles loyalty program contributes over 90% of clinic collections, with experiential marketing aiding customer retention and spending. - Marketing efforts, including chatbots and automation, aim to improve customer acquisition, driving incremental revenue. - The combination of enhanced utilization, expansion, and marketing investment is expected to drive topline growth without proportionate increases in overhead, aiming to improve profitability alongside revenue.

- Kaya Limited aims to improve growth beyond the current 7%-8% seen in Q1 FY ‘26, targeting industry growth levels of 13%-14% through several initiatives. - Focus on better utilization of existing infrastructure and clinics to increase customer count without significantly adding costs. - Investment in marketing and customer acquisition to drive top-line growth from existing clinics. - Expansion program underway, with plans to open around eight new clinics by September/October 2025, expected to contribute to revenue growth. - The combination of increased utilization and new clinic openings is expected to improve operating margins and profitability while maintaining current corporate overheads. - Equity dilution through fundraising is expected to reduce interest cost, enhancing savings and supporting the road to profitability. - Management is optimistic that these strategic efforts will translate into incremental revenue growth and improved bottom-line performance over the medium term.

- Kaya Limited is engaged in an expansion program and has opened multiple new clinics: two in Q1 FY ‘26 (Yelahanka in Bangalore and Starling Mall in Noida) and one already in Q2, with five more signed, targeting around eight clinics by September-October 2025 (Page 6). - The company invested in 31 new dermatology machines across multiple categories in Q1 FY ‘26 to uplift customer experience and outcomes (Page 3). - Funds raised through preferential allotment are expected to be used for marketing and customer acquisition to better utilize existing infrastructure and drive revenue growth (Pages 5-6). - No explicit mention of other future capex plans or strategic investments beyond clinic expansion and related marketing investments was made in the call (Pages 3-7).

- Kaya Limited is currently completing a preferential allotment expected by the end of August 2025. - Post completion, the board will decide on proceeding with a rights issue; it is still "on the cards" but not finalized. - Preferential allotment route was chosen to be simpler and quicker to support expansion plans. - The strategic investor coming in through preferential allotment brings experience and pedigree to support growth. - Previous plans for a Rs. 300 crore rights issue have been modified to Rs. 75 crore via preferential allotment currently. - No final decision yet on board seats for new investors. - Fundraising aims to reduce interest costs through equity dilution, aiding the road to profitability.

The document does not explicitly mention the current or expected order book or pending orders for Kaya Limited. However, relevant points related to clinic expansion and growth outlook are: - Kaya opened 2 new clinics in Q1 FY ’26 (Yelahanka in Bangalore and Starling Mall in Noida). - An additional 1 new clinic opened in Q2 FY ’26, with 5 clinics already signed. - By September-October 2025, total new clinics expected to be around 8. - Beyond October 2025, no forward-looking clinic opening guidance was provided. - Expansion and new clinic openings are part of the growth and revenue strategy. - The Board is expected to decide on fundraising (preferential allotment followed by possible rights issue) which will support growth plans. No specific figures on order backlog or pending orders are disclosed in the call transcript.